Hims & Hers Health (HIMS) Cash from Operations Growth (3y) (2022 - 2026)
Hims & Hers Health (HIMS) Cash from Operations Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 27.85% |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | 111.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 111.22% |
| Dec 31, 2025 | 123.24% |
| Sep 30, 2025 | 191.81% |
| Jun 30, 2025 | -44.06% |
| Mar 31, 2025 | 96.80% |
| Dec 31, 2024 | 210.10% |
| Sep 30, 2024 | 94.36% |
| Jun 30, 2024 | 346.77% |
| Mar 31, 2024 | 53.55% |
| Dec 31, 2023 | 337.47% |
| Sep 30, 2023 | 100.27% |
| Jun 30, 2023 | 379.95% |
| Mar 31, 2023 | 56.42% |
| Dec 31, 2022 | -202.94% |
| Sep 30, 2022 | 213.75% |